The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2010Characterization of PARK16
Objective/Rationale:
Recently, a novel region of the genome containing genetic information predisposing to the development of Parkinson’s disease has been discovered through a collaborative study of... -
Rapid Response Innovation Awards, 2010Deciphering the Molecular Effects of Alpha-Synuclein in the Nucleus: DNA Binding and Transcriptional Dysregulation
Objective/Rationale:
A-synuclein, the main component of Lewy bodies, is thought to be present mostly on nerve terminals. Although the function of a-synuclein is unclear, its presence in the nucleus of... -
Rapid Response Innovation Awards, 2010Susceptibility Genes for Antipsychotic-induced Extrapyramidal Symptoms as Modifier Genes in Parkinson's Disease and L-dopa Treatment Response
Objective/Rationale:
The use of antipsychotic drugs, all of which block dopamine D2 receptors, to treat schizophrenia and other psychotic states is associated with the development of motor acute... -
Rapid Response Innovation Awards, 2010Biofeedback-based Motor Learning to Ameliorate Freezing of Gait
Objective/Rationale:
Our objective is to demonstrate that an intervention program based on motor learning principles can be applied to train subjects with Parkinson's disease (PD) who suffer from... -
Rapid Response Innovation Awards, 2010The Role of LRRK2 in Wnt Signaling In Vivo
Objective/Rationale:
We have preliminary evidence that LRRK2, which is a key protein in Parkinson’s disease (PD), may have a role in an important cellular process called Wnt signaling. Thus it is... -
Therapeutics Development Initiative, 2010Development of an Adult Adherent Allogeneic Stem Cell Product for Treatment of Parkinson's Disease
Objective/Rationale:
Previously published data illustrates that MultiStem®, an adult stem cell product approved by the FDA for Phase I studies in humans, works through multiple mechanisms of benefit...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.